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Discussion
Case presentation
A 31-year-old male developed insulin-dependent diabetes mellitus at
age 12. His clinical course has been characteristic of many insulin-
dependent diabetics: he developed hypertension at age 27, the nephrot-
ic syndrome at age 31, and azotemia at age 32; he required dialysis at
age 33. Extrarenal complications essentially are limited to mild retinop-
athy, which has not required therapy.
After one month of dialysis, he was admitted to the hospital for
cadaver-donor renal transplantation (Fig. 1). He was given 17 mg/kg of
cyclosporine orally and 60 mg of methylprednisolone intravenously
prior to surgery. Following transplantation, an immediate diuresis
ensued. Cyclosporine was continued at 17 mg/kg/day and oral predni-
sone was instituted at 30 mg/day. By the third day after transplantation,
the patient's serum creatinine fell to 1.9 mg/dI. On day 5, however, the
patient became oliguric without having evidence of graft tenderness or
fever. Moderate gastric dilation was noted, raising the question of
whether the cyclosporine had been adequately absorbed. A renal
sonogram disclosed no abnormalities. Percutaneous biopsy of the
transplant was performed on day 5. On day 6, the serum creatinine rose
to 4.5 mg/dl. Microscopic inspection of the biopsy specimen revealed a
dense interstitial infiltrate of mononuclear leukocytes, primarily lym-
phocytes, without evidence of significant vasculitic injury. Mainte-
nance therapy of cyclosporine and prednisone was continued. A
decision to treat the rejection reaction with the mouse antihuman T-cell
monoclonal antibody T12 (anti-T12) was made; the patient did not react
to intradermal challenge with the antibody. The patient received 200 /Lg/
kg of anti-Tl2 by intravenous infusion on the 6th postoperative day, and
anti-T12 was continued for a total of 10 days. Daily serum creatinine
determinations gave evidence of improving graft function following the
first treatment with monoclonal antibody. At the end of anti-T12
therapy, a second renal biopsy revealed disappearance of the cellular
infiltrate and essentially normal renal architecture.
The patient has not sustained a second rejection reaction, and his
serum creatinine is 1.7 mg/dl more than one year after anti-T12 therapy.
At present, he is maintained on an immunosuppressive regimen of
cyclosporine, 8 mg/kg/day orally, and prednisone, 20 mg every other
day.
DR. TERRY B. STROM (Director, Renal Transplant Service,
Beth Israel Hospital, the Charles A. Dana Research Institute,
and the Harvard-Thorndike Laboratory; and Associate Profes-
sor of Medicine, Harvard Medical School, Boston, Mass.): The
therapeutic program utilized for this patient epitomizes the
recent radical departure from the time-honored standard in
virtually all renal transplant programs of treatment with azathi-
oprine plus prednisone for maintenance therapy, and of high-
dose corticosteroid for acute antirejection therapy. An extreme-
ly effective and steroid-sparing approach to patient manage-
ment suddenly has emerged. This effective and relatively safe
program has dramatically improved the outcome of cadaver-
donor renal transplantation and probably will have a major
impact on the number of patients entering renal transplant
programs; early results indicate the surprising safety of this
treatment for high risk—that is, older—patients. Since this
patient's transplant, several other individuals at our institution,
usually diabetic, have experienced very early rejection episodes
while receiving the same treatment. As a consequence, we now
give patients 5 mg/kg of cyclosporine in gel form intravenously
prior to surgery in an attempt to assure bioavailability. The
immunology of the allograft response and the mechanisms by
which the agents used in clinical transplantation alter the
allograft response (that is, the response of the host to allogeneic
tissue) is the topic of this discourse. In the following discussion
I will attempt to summarize briefly the fundamental nature of
immunologic responses against transplanted tissues and the
means available to us for minimizing the magnitude of such
responses, thereby facilitating engraftment.
Histocompatibility
Even primitive organisms have the ability to distinguish
between self and non-self. Clearly, all mammalian species
studied possess a single chromosomal region that encodes for
the strong, or major, transplantation antigens [1]. These major
histocompatibility antigens are highly polymorphic cell surface
structures whose recognition by the host enables distinction
between sell and non-self. In humans, genes for the major
histocompatibility complex (MHC) are aligned in close proximi-
ty to each other on the sixth chromosome Ill, 2]. The MHC in
humans was named the HLA system (originally for human
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Fig. 1. Clinical course of a 31-year-old white male with end-stage
diabetic nephropa thy following renal transplantation.
leukocyte antigen). To date, at least six gene loci controlling the
expression of major histocompatibility antigens have been
identified (Fig. 2). In addition to histocompatibility genes, the
MHC contains genes that code for the biosynthesis of several
complement components [3].
The HLA antigens are glycoproteins present in varying
quantities on most cell surfaces, except mature red cells.
Because circulating mononuclear leukocytes are readily har-
vested, they are used for HLA typing. We now can distinguish
between class-I HLA molecules, which are expressed on virtu-
ally all cell surfaces, and class-Il HLA molecules, which are
present on the surface of only a few cell types [1, 2]. Cells that
express class-Il antigens include B lymphocytes, some mono-
cytes, and other antigen-presenting cells, as well as T lympho-
cytes that become "class IT-positive" when activated.
The three well-defined class-I loci are the HLA-A, -B, and -C
cell-surface antigens, products of different gene loci but having
an identical basic structure. Each consists of a 44,000 dalton
transmembrane glycoprotein heavy chain, which carries the
antigenic specificity [4], noncovalently associated with a non-
polymorphic 11,500 dalton beta2-microglobulin subunit [5] en-
coded by a gene on chromosome 15 (Fig. 2). Class-I antigens
usually are detected with a complement-dependent microlym-
phocytotoxicity assay. Mononuclear leukocytes to be typed are
incubated with human sera containing HLA antibodies of
known specificity. The cell suspension is exposed to comple-
ment and eosin or trypan blue dye; cells bearing the target
antigen sustain membrane damage, which is recognized by
intracellular uptake of the dye 161.
Linked to the serologically denned HLA-A, -B, and -C
antigens, albeit separate from them, is another genetic region,
called HLA-D, which codes for class-Il HLA molecules—
glycoproteins that trigger the proliferative response that occurs
when lymphoid cells with mismatched HLA haplotypes are
cultured together in a mixed lymphocyte culture (MLC). It was
thought initially that incompatible HLA-A and -B antigens
caused a positive MLC assay. However, family studies clearly
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Fig. 2. Genes of the HLA complex are located within the short arm of
chromosome 6 (top). Map of the HLA region (bottom) depicts the
spatial relationship (recombination units) between genes encoding
class-I HLA-A, -B, and -C antigens (broken lines), class-Il HLA-DR,
-DS, and -SB antigens (solid lines), as well as complement components
(stippled area).
showed that a separate region, namely HLA-D, evokes a
proliferative MLC response when there is a mismatch, regard-
less of the presence of HLA-A, -B, and -C identity [1, 2, 6].
Compatibility of HLA-D is assessed by an adaptation of the
standard MLC assay. The stimulating mononuclear leukocytes
obtained from a prospective graft donor first are treated by x-
irradiation or mitomycin C to make the proliferative response
unilateral. Mononuclear leukocytes from the prospective recipi-
ent are utilized as responder cells and are cultured together with
the donor's stimulator cells. Responder cells react vigorously to
test cells expressing foreign HLA-D antigens, but weakly or not
at all to cells that express antigens similar to their own [1, 2, 61.
The HLA-D antigens are class-TI antigens homologous to
murine Ia antigens. Each antigen molecule consists of two
transmembrane glycoprotein chains of approximately 28,000
(beta) and approximately 34,000 (alpha) daltons and lacks beta2-
microglobulin [7—10]. In addition, a third chain is found intracel-
lularly in association with the class-I! molecules. It is likely that
this chain, designated invariant, is important in the assembly
and eventual transport of class-Il molecules to the surface of
the plasma membrane.
The HLA-D region occupies an expanse of approximately 4
centimorgans between the HLA-B locus and the glycoxylase
(GLO) locus complex. A well-characterized genetic locus of
serologically defined antigens designated HLA-DR (D-related)
are typed by complement-dependent microlymphocytotoxicity,
using T cell-depleted, B cell-, and macrophage-enriched mono-
nuclear leukocytes and sera of known DR specificity [6],
whereas HLA-D alleles are identified, as indicated above, by
MLC testing. Many researchers initially believed that DR
antigens were solely responsible for stimulating MLC reactiv-
ity; however, this appears unlikely. Although DR antigens are
indeed potent stimulator antigens in the MLC, these antigens
are not the only antigens that elicit primary or secondary MLC
reactions [2]. We now know that there are a minimum of 3 class-
II HLA loci encoded within the HLA-D region: DR, DS, and
SB [11]. The DR locus is the homologue of mouse I-E molecules
[7, 8]. The DS locus is encoded with tight linkage dysequilibri-
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Fig. 3. Structures of class-I and class-Il HLA molecules and immuno-
globulin. Certain domains (stippled areas) of these proteins are remark-
ably homologous and may represent reduplication of a common ances-
tral gene.
Fig. 4. Adhesion of T4-positive helper T cells to DR-positive allogeneic
cells results from the attachment of the T-cell antigen receptor to the
unique polymorphic (antigeneic) specificities located on the beta-I
domain of DR as well as the interaction of the T4 protein with ill-
defined, nonpolymorphic regions of the DR molecule.
urn to DR such that it is uncertain as to whether the DS gene lies
centro- or teleomeric to ("left" or "right" of) DR on chromo-
some 6. The DS alpha-chain molecule shares homology to
alpha-chain of murine I-A molecules [12]. This locus is identical
to systems that also have been designated as DC, MB, and Te
[13—15]. The SB locus is centromeric to DS and DR. The DR
beta chains and both alpha and beta chains of DS and SB bear
the unique polymorphisms that characterize these loci [10].
Fig. 5. Adhesion of T8-positive cytotoxic T cells to allogeneic target
cells results from the attachment of the T-cell antigen receptor to the
unique polymorphic (antigeneic) specificities located on the alpha-I
domain of class-I HLA molecules as well as the interaction of the T8
protein with ill-defined nonpolymorphic regions of class-i HLA
molecules.
Furthermore, data obtained by serologic analysis and gene
cloning indicate that additional, and perhaps many, loci are
encoded within the HLA-D region.
Whereas class-I and class-Il major histocompatibility anti-
gens bear distinguishing characteristics, similarities also exist
between certain domains of these glycoproteins—similarities
that are shared to some extent with the thy-i antigen, beta2-
microglobulin, and immunoglobulin (Fig. 3) [16]. The constant
region of immunoglobulin beta2-microglobulin, the extracellular
protein domains adjacent to the plasma membrane of class-I
alpha chains (alpha3 domain), and class-Il alpha and beta chains
(alpha2 and beta2 domains) are related molecules, as evidenced
by the amino acid sequences determined by protein analysis or
deduced from DNA analysis. The domains of class-I and class-
II HLA glycoproteins that bear the polymorphisms—that is,
HLA antigenic sites—do not, however, exhibit the same degree
of homology.
In analyzing potential donors for kidney transplantation, one
should remember that presensitization to certain minor non-
HLA as well as major HLA antigens is important for tissue
matching. It has long been known that compatibility for red cell
ABO antigens between donor and recipient is of the utmost
importance, as preformed natural anti-A and anti-B antibodies
constitute a strong barrier to successful engraftment. Certain
other preformed antibodies present at the time of transplanta-
tion portend an immediate vasculitic form of graft destruction
(hyperacute rejection). It is clear that recipients harboring
antibodies against class-I, but not class-I!, antigens of the donor
are at high risk for this process. Multiparous or frequently
transfused women and patients who previously have rejected an
allograft are all at high risk of harboring such antibodies.
Presensitization against a non-HLA antigen system shared
Fig. 6. AThe activation sequence leading to
the proliferation of alloreactive T cells
includes antigen, interleukin-1, and
interleukin-2. Macrophage activating factor
has proved to be identical to gamma-
interferon. Allograft rejection is a complex
event that results from the cytodestructive
effects of activated B lymphocytes, helper T
cells, cytotoxic T cells, and activated
macrophages. (Adapted froni diagram
prepared by Hospital Practice, January 1983)
between the endothelial surface of peritubular capillaries and
monocytes also heralds accelerated rejection in the few patients
who bear such antibodies [17].
Because the sixth chromosome is paired, each individual
inherits genes for eight HLA loci antigens. Four antigens are
inherited from each parent. Special tissue typing laboratories
can readily define the phenotype of the HLA-A, -B, -C, and DR
antigens by serologic techniques [6]. Typing for the newly
discovered SB and DS loci is not yet possible in clinical
practice. By simple mendelian autosomal inheritance, any given
pair of siblings will have a 25% chance of having identical
haplotypes; 50% will share one haplotype, and the remaining
25% will be completely incompatible [1, 6]. By definition, each
parent and child share one haplotype. Matching of HLA
antigens is extremely valuable in choosing donor and recipient
pairs for renal transplantation using closely related family
members [1]. A clear-cut gene-dose effect is observed when the
rates of engraftment are compared for recipients of familial
grafts matched for zero, one, or two haplotypes. Whereas 90%
to 95% of HLA-identical sibling-donor renal grafts function at
one year, the one-year graft survival for one-haplotype matched
(sibling or parent) and HLA-incompatible siblings treated with
traditional regimens are 75% and 60%, respectively.
As the HLA system is the most polymorphic genetic system
known, it is all but impossible to find perfectly matched
cadaver-kidney donors for prospective recipients. As a conse-
quence, it has been important for us to learn that matching for
HLA-DR alleles has a greater impact on cadaveric renal graft
outcome than does matching for class-I antigens [18—2 1]. In-
deed, most of the benefit of matching for class-I antigens
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Fig. 6. B Azathioprine is metabolized in vivo to 6-mercaptopurine, an antimetabolite that blocks DNA replication, thereby inhibiting proliferation
of effector lymphocytes. (Figs. 6B, C, and D reprinted from Hospital Practice, January, 1983.) C Corticosteroids block the release of IL-I, thereby
inhibiting the IL-i—dependent re/ease of IL-2. D Cyclosporine prevents IL-2 release and thus blocks antigen driven T-cell proliferation. (Drawing
by Bunji Tagawa)
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observed prior to the advent of HLA-DR matching seems
attributable to fortuitous HLA-DR matching resulting from the
strong linkage dysequilibrium between HLA-B and DR-locus
antigens. Results thus far indicate that cadaveric engraftment
using conventional immunosuppression is especially abetted if
matching for both DR alleles is accomplished [18—211.
The special importance of serologic HLA-DR locus matching
was foreshadowed by earlier observations indicating the predic-
tive value of HLA-D matching by means of the MLC assay [22].
Of particular interest are reports demonstrating that quantita-
tive MLC testing for potential recipient and donor MLC combi-
nations can be used effectively to ascertain which haploidenti-
cal donors within a family will yield rates of engraftment
rivaling those obtained using HLA-identical sibling donors [22,
23]. Hence the magnitude of MLC responses generated in
response to class-IT, HLA-D region mismatches may be a more
powerful typing tool than is genotypic matching for HLA. Other
data also indicate that low recipient antidonor MLC responses
predict successful engraftment for cadaver-donor grafts and
thereby underscore the importance of matching for HLA-D
region antigens [24]. Unfortunately, the time constraints im-
posed by the limits for preservation of functional cadaveric
kidneys (72 hours) preclude the standard 5- to 6-day MLC
assay, which measures antigen-driven DNA synthesis. The
possibility that rapid MLC typing can be utilized for HLA-D
matching is raised by our almost fortuitous observation that
quiescent T lymphocytes lack receptors for insulin, whereas
insulin receptor proteins are expressed on activated cells during
the early, that is, Gl cell cycle phase of T-cell activation [25—
27]. More recently, a panel of monoclonal antibodies has been
used to mark the appearance of several surface proteins that are
also expressed de novo during the Gl phase of T-cell activation
[28]. These antibodies enable us to ascertain the magnitude of
T-cell activation within 12 hours of initiating MLC assays [29].
The a/b graft response
As illustrated in the foregoing discussion, host responses
against HLA molecules, especially class-IT molecules, are a
formidable barrier to successful renal engraftment. The cellular
response directed against mismatched HLA antigens is T-cell
dependent. The constituents and the molecular basis of the
allograft response have been the subject of intensive investiga-
tion. I would like to discuss some of the pertinent features of
this response.
All mature T lymphocytes bear the T3 protein as a distinctive
surface marker, whereas two complementary, essentially non-
overlapping, functional T-cell subsets can be identified by
expression of either the T4 or T8 surface protein [30]. The T4+,
helper T lymphocytes are programmed to preferentially recog-
nize class-IT HLA molecules such as DR, DS, and SB; T8+,
cytotoxic T lymphocytes preferentially recognize class-I HLA-
A, -B, and -C locus molecules [31—34]. The T4 protein itself
binds to a nonpolymorphic region of class-Il HLA antigens
(Fig.4), whereas the T8 protein serves a similar function in
binding to class-I MHC antigens [34, 35] (Fig. 5). The T-cell
receptor protein for antigen is almost certainly a 92,000 dalton
heterodimer that is not associated with T4 or T8 but is linked to
the T3 membrane protein [35, 36]. Hence, a dual receptor model
for T-cell recognition of antigen appears valid. Activation of
helper T cells by class-TI MHC antigens stimulates the release
of a macrophage stimulant, perhaps the same molecule as
colony-stimulating factor [37], and the formation of receptors
for insulin [38—40], transferrin [41], interleukin-l (IL-l) [42],
and interleukin-2 (IL-2) [43] (Fig. 6). Cytotoxic T lymphocytes
stimulated by class-I HLA antigen develop IL-2 receptors [43].
Subsequently, stimulated macrophages and other accessory
cells release IL-l, which in turn stimulates the release of IL-2
[44]. Tnterleukin-2 interacts with specific interleukin-2 receptors
expressed on activated helper and cytotoxic T cells [44]. This
interaction stimulates the initiation of DNA synthesis and
eventual clonal proliferation of receptor-bearing cells [44].
Moreover, the continued viability of activated T-cell clones is
interleukin-2--dependent. Interleukin-2 in turn causes the re-
lease of gamma-interferon [45], which activates macrophages
[46] as well as B-cell growth factors that stimulate the prolifera-
tion of antigen-activated B cells [47, 48].
Another helper T-cell product whose release might be stimu-
lated by IL-2 is cytotoxic differentiation factor (Fig. 6A).
Whereas IL-2 causes clonal growth of cytotoxic T cells, cyto-
toxic differentiation factor activates and thereby unleashes the
cytotoxic potential of noncytotoxic T8-positive T cells [49, 50].
In brief, activation of helper T cells by alloantigen and IL-l
stimulates the release of a variety of lymphokines from helper T
cells that in turn activate macrophages, cytotoxic T cells, and
antibody-releasing B cells (Fig. 6A). These factors also support
clonal expansion and viability of antigen-activated T and B
cells. Unmodified rejection results from the cytodestructive
effects caused by cytotoxic T cells, activated macrophages, and
antibody [51] (Fig. 6A). Although cytotoxic T cells are the
dominant cell type that infiltrates the allograft during rejection
episodes in experimental models [51, 52], and in most clinical
rejections [53, 54], the transcendent importance of helper T
cells in the events of rejection almost certainly derives from the
"endocrine" role of helper T cells in providing the various
soluble growth and activation signals required during the allo-
graft response (Fig. 6A). That helper T cells are preeminently
important in the rejection of vascularized organ transplants has
been proved in experiments in which reconstitution of allograft
immunity has been accomplished by injection of alloactivated
helper T cells into T cell—deficient animals [55, 56].
Immunosuppressive therapy
The immunosuppressive activities of each of the therapeutic
agents used in clinical transplantation directly interfere with
one or another of the several steps in the "allograft response"
(Fig. 6A). Azathioprine, an oral purine analogue, one of whose
in-vivo metabolites is 6-mercaptopurine (6-MP), has been the
mainstay of antirejection therapy since it was introduced in
1961 as maintenance therapy for renal transplant recipients.
Azathioprine is the S-imidazolyl derivative of, and is metabo-
lized in vivo to, 6-MP [57]. This purine analogue is an antime-
tabolite with multiple activities. Metabolites of azathioprine are
incorporated into cellular DNA, inhibit purine nucleotide syn-
thesis and metabolism, and alter the synthesis and function of
RNA. As lymphocytic RNA synthesis, DNA synthesis, and
proliferation result from antigenic stimulation, azathioprine acts
at an early step in either B- or T-lymphocyte activation during
the proliferative cycle of effector lymphocyte clones (Fig. 6B).
Azathioprine is administered on a continuous basis. Even
temporary cessation of administration in the early posttrans-
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plant period results in a high rate of graft failure [581. Although
azathioprine is a powerful inhibitor of primary immune respons-
es, it has little or no effect on secondary responses. The drug is
useful in preventing acute rejection, but it is not valuable in the
therapy of ongoing rejection.
Corticosteroids were first used in transplantation to reverse
acute rejection reactions in patients treated with maintenance
doses of azathioprine. It is now customary to use modest doses
of a corticosteroid in maintenance protocols that also utilize
azathioprine or cyclosporine; high doses of corticosteroids are
used to treat acute rejection. Through mechanisms quite dis-
tinct from the action of azathioprine, corticosteroids directly
inhibit antigen-driven T-celi proliferation. Whereas high con-
centrations of corticosteroids lyse mouse T cells, human T cells
are not lysed by corticosteroids; nonetheless T-cell prolifera-
tion is inhibited in human tissue culture [59]. Recent in-vitro
data suggest that steroids reverse in-vivo rejection episodes by
preventing the production of IL-2, thereby denying activated T
cells an essential trophic factor [601. Steroids do not directly act
on the interleukin-2—producing T cell, but they inhibit produc-
tion of this lymphokine by preventing monocytes from releasing
IL-i [611, thereby blocking interleukin- 1—dependent release of
interleukin-2 from antigen-activated T cells (Fig. 6C). Other
effects of steroids on monocytes, such as inhibition of chemo-
taxis, also are likely to be important [621.
The fungal metabolite cyclosporine is a cyclic endecapeptide
[631, which shares with corticosteroids the capacity to block the
entry of activated T lymphocytes to the S phase of the cell cycle
[64]. Unlike corticosteroids, cyclosporine does not inhibit the
capacity of all, or even most, accessory cells to release IL-l
[65]. Cyclosporine does, however, block IL-2 release (Fig. 6D)
from activated helper T lymphocytes [65, 66]. The release of
other lymphokines, such as gamma-interferon, by activated T
cells also is inhibited by cyclosporine [67], whereas the expres-
sion of IL-2 receptors [68] and the responsiveness of activated
T lymphocytes to lymphokines are not blocked [69, 70]. Coinci-
dent with the drug-induced inhibition of helper T-ceil function,
cyclosporine spares, at least in a relative sense, the activation
of suppressor T cells in vitro and in vivo [69—72]. In experimen-
tal models, cyclosporine, like azathioprine, does not erase
presensitization. Hence, the overall effect of cyclosporine is to
skew de-novo immune responses into the suppressor mode. In a
clinical setting, a controlled, multicenter European trial showed
therapy with cyciosporine alone to be superior to conventional
multidrug regimens in treating recipients of cadaveric-donor
renal allografts [731; we were disappointed in our own similar
efforts [74]. More recently, we [74] and others [75, 76] have
combined cyclosporine with low-dose steroids with remarkable
effectiveness. Overall, the results of controlled multicenter
trials conducted in Europe [73, 771, Canada [78], and our own
unit [74] suggest that cyclosporine therapy results in a 15% to
20% improvement in one-year cadaveric-donor graft survival as
compared to results from programs utilizing azathioprine and
prednisone. It is likely that combined cyclosporine and steroid
therapy is so effective because of the ability of both agents to
abrogate IL-2 release through different sites of action. Whereas
cyclosporine acts predominantly on helper cells, corticoste-
roids prevent IL-l release from accessory cells. The intent of
this review is not to dwell on complications of drug therapy, but
it must be noted that cyclosporine is extremely nephrotoxic in a
dose-dependent fashion [73—78]. This most unattractive feature
of the agent creates formidable, but not unresolvable, problems
in clinical practice [73—78].
The extraordinary effectiveness of heterologous antilympho-
cyte (especially antithymocyte) antibodies in prolonging en-
graftment of murine allografts [79, 80] has prompted a protract-
ed and, at times, elusive search for similarly effective antibodies
for use in clinical transplantation. Heterologous antilymphocyte
antibodies, however, have been employed successfully to re-
verse rejection episodes [81]. These conventional, polyclonal
antibodies vary from lot to lot with respect to their relative and
absolute content of desired as well as unwanted antibodies.
Well-defined monoclonal antihuman lymphocyte antibodies po-
tentially afford a practical and satisfactory solution to these
difficulties. Whereas the addition of prophylactic antilympho-
cyte globulin to conventional immunosuppressive protocols
does not improve long-term renal transplant success rates,
clinical studies have demonstrated that these antibodies are
very effective in reversing ongoing rejection crises [811. Conse-
quently, several groups are now studying the efficacy of mono-
clonal antihuman T-lymphocyte antibodies in the treatment of
renal transplant rejection episodes. We have embarked on a
study in which the monoclonal mouse antihuman Tl2 antibody
has been employed to treat rejection episodes occurring among
renal allograft recipients [74, 82]. The choice of Tl2 was not
capricious; several attributes were important in its selection.
First, we purposefully selected an antibody that reacts with
nearly all mature, postthymic, but not thymic precursor, T
cells. Postthymic T cells mature from thymic stem cell precur-
sors. The intent of monoclonal antibody therapy is to destroy
peripheral lymphoid populations, as these peripheral T cells are
responsible for rejection [51—56]. With cessation of therapies
targeted solely at peripheral T cells, a permanent T-cell immu-
nodeficiency state is averted by the repopulation of peripheral
lymphoid tissues by newly maturing T cells derived from the
"unattacked" thymus. An antibody such as Tll, which de-
stroys thymic stem cells, may create a long-lived T-cell immu-
nodeficiency state. We thus considered for clinical use the two
monoclonal antibodies that react with peripheral T cells, but not
thymic stem cells, OKT3 and anti-T12. The former has been
demonstrated by others to strikingly reverse rejection episodes
[83, 841. A mouse antihuman IgG antibody, OKT3 defines a
l9Kd integral membrane protein that is intimately associated
with the T-cell antigen receptor [35]. Interaction of OKT3,
which is essentially an antiantigen receptor antibody, with the
T3 protein upon T cells mimics antigen activation, causing T
cell proliferation and a release of lymphokines (Fig. 7A) [35].
We speculated that this property might not be ideal. Moreover,
shortly after OKT3 binds to T cells, the antibody-surface
antigen complex is shed from the cell surface (Fig. 7A) [3, 5, 6].
As destruction of circulating lymphocytes probably results from
opsonization by cells that capture circulating materials by
virtue of receptors for immune complexes, the loss of the
antigen-antibody complex can hinder this process. By compari-
son, the fate and effect of anti-T12 on T cells studied in vitro are
simple and dull (Fig. 7B). The T cells are not activated, and the
antibody remains on the T-cell membrane. For these reasons,
we selected anti-T12 (an 1gM antibody defining a l2OKd mem-
brane protein) for use in renal transplantation after this anti-
body was noted to reverse acute graft-versus-host disease in an
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Fig. 7. A As the T3 protein is noncovalently linked to the T-cell receptor for antigen, anti-T3 inhibits antigen recognition by T cells. Anti-T3 also
causes rapid disappearance or modulation of the T3 protein as well as T-cell activation and proliferation. B Anti-T12 coats T cells, thereby
facilitating lysis by tissue-fixed phagocytes. (Reprinted with permission from Hospital Practice, January 1983. Drawing by Bunji Tagawa)
allogeneic bone marrow transplant recipient [85]. Early results
suggested that both OKT3 and anti-T12 antibodies are superior
to high-dose corticosteroids in initially reversing virtually all
cellular rejection episodes, that is, a rejection dominated by an
infiltrate of T cells and macrophages. More extensive trials will
be required to ascertain the relative merits of these two
antibodies. Preliminary studies suggest that "rebound" rejec-
tion episodes rarely if ever follow cessation of anti-T12 therapy,
whereas such episodes are commonly observed when OKT3 is
used. Second, febrile and anaphylactoid reactions occur far less
commonly with anti-T12 than with OKT3 administration. Both
antibodies fail to reverse some vasculitic-type rejection reac-
tions. Given the availability of numerous monoclonal antibodies
that define various proteins expressed uniquely on discrete
lymphocyte subpopulations, it would not be surprising if an
extremely flexible and individualized approach to antirejection
therapy soon becomes a reality. Thus, the utilization of OKT3
and anti-Tl2 antibodies reflects only the initial, and not the
ultimate, stage of antirejection therapy with monoclonal
antibodies.
Within the past several years, immunosuppressive protocols
at our center have been revised. Cyclosporine now has sup-
planted azathioprine as the initial agent used for maintenance
therapy in concert with low doses of corticosteroids (for
example, 30 mg/day for the first 14 days) in all but HLA-
identical sibling donor and recipient pairs. Grafts obtained from
haplomismatched living-related donors or unrelated donors
evoke powerful allograft responses. Recognition of class-I!
HLA molecules by the host is of quintessential importance in
initiating this immune response. As a consequence, cyclospor-
me is utilized in such circumstances because of the failure of
traditional therapies to yield a high rate of engraftment. We do
believe that cyclosporine, which blocks IL-2 release, combined
with low-dose corticosteroid therapy, which inhibits IL-i re-
lease, affords an opportunity for classic pharmacologic syner-
gism. For antirejection therapy, we now use anti-T12 therapy
rather than high-dose corticosteroids. In addition to the im-
provement in therapeutic efficacy offered by T12, we avoid the
undesired systemic toxicity caused by corticosteroids. The
relative efficacy of cyclosporine and low-dose steroids versus
another departure from tradition, donor-specific transfusions
for haplomismatched living-related donors, is not known. When
feasible, we employ DR-matched cadaveric donor organs.
Although DR matching does not guarantee compatibility for all
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class-Il HLA molecules, this approach is useful, probably
because of the dampening effect that such matching has on
helper T cell activation. The usefulness of rapid MLC matching
soon will be tested; this test theoretically would provide more
information about the capacity of donor tissues to activate the
helper T-cell—dependent allograft response in vitro. Today 85%
of recipients of first cadaveric donor kidneys can be successful-
ly engrafted (at 2 years) if a maintenance protocol of cyclospor-
me and low-dose corticosteroids with antirejection therapy of
T12 monoclonal antibody is used [86]. These remarkable im-
provements offer great promise to patients with end-stage renal
failure because dialysis does not fully rehabilitate most of them
[87]. These developments also offer society a respite from the
staggering financial and psychic costs of dialytic therapy.
Further improvements appear imminent.
Questions and answers
DR. JEROME P. KASSIRER: How does cyclosporine work at a
cellular level?
DR. STROM: The exact nature of the mechanism by which
cyclosporine exerts its effects is not well understood. It is a
very lipophilic molecule, and I would guess that an effect on the
membrane is important. Perhaps cyclosporine blocks the trans-
location of calcium that is normally engendered during T-cell
activation.
DR. ANDREW LEVEY (Division of Nephrology, NEMC): You
referred to the salutary effects of HLA-DR matching and to
pretransplantation blood transfusions. Should we adopt policies
of deliberate transfusions and widespread DR matching, or
should we instead employ the new immunopharmacologic ap-
proach that you laid out?
DR. STROM: This is an important question. However, the
experience with cyclosporine is not extensive enough for me to
answer with confidence. Early returns indicate that the transfu-
sion effect may still be very important in patients receiving
cyclosporine. It is my guess that since cyclosporine works
specifically at the level of the helper cell, HLA-DR matching,
which results in diminished helper T-cell activation, might
become less important in clinical transplantation.
DR. NICOLAOS E. MADIAS: Have you identified different
subsets of cadaveric graft recipients in terms of treating these
patients with a particular protocol?
DR. STROM: Unfortunately, we only have a uniform policy
and have not been able to individualize therapy. One of the
ways in which therapy might be individualized relates to the
variability in assimilation of cyclosporine. Measuring serum
levels of cyclosporine has not helped us a great deal. As a
result, we have depended heavily on renal biopsy to help us
distinguish episodes of graft dysfunction due to rejection from
those due to cyclosporine nephrotoxicity. As cyclosporine
nephrotoxicity does not produce interstitial nephritis, the diag-
nosis of acute rejection can be readily made.
DR. KASSIRER: Can we pause to explore the value of renal
biopsy in these patients? A renal biopsy is a rather safe
procedure in the transplant patient, especially because the
kidney is readily accessible. More important, because the new
methods of treatment you described are more effective as well
as more toxic, there is a substantial premium in knowing
whether the patient is either rejecting the graft or has cyclospor-
me toxicity. For this reason it seems to me that renal biopsy is a
more useful tool in transplantation now than it was when high-
dose steroid was the only available treatment. Even given these
special features, a critically important factor is the accuracy of
the histologic diagnosis. Many have considered the histologic
characteristics of rejection to be relatively nonspecific. How
confident are you that acute rejection can be distinguished from
other disorders that cause renal insufficiency in the transplant
patient?
DR. STROM: Let us examine a hypothetical situation that
often occurs with cyclosporine therapy. Following a diuresis,
the serum creatinine stabilizes at some unacceptably high level,
say 3 mg/dl, in the absence of fever and graft tenderness. The
classic signs of rejection are somewhat less common in rejec-
tion episodes occurring in patients treated with cyclosporine,
and a bedside diagnosis of rejection is insecure in such patients.
We would first attempt to rule out, usually by renal ultrasound,
an anatomic problem such as obstruction or a urine leak. In the
event of a normal ultrasound we biopsy the kidney, looking for
evidence of rejection. We take the presence of a substantial
interstitial infiltrate, in the absence of severe vasculitis, as
sufficient reason for the initiation of antirejection therapy. On
the other hand, patients with a chronic vasculitic injury rarely
respond to antirejection therapy. Hence, the presence of severe
vasculitis, particularly chronic vasculitis manifested by en-
croachment of the vessel wall with fibrosis, is a reason to
discontinue further antirejection therapy. I think an important
function of renal biopsy is sparing patients unneeded courses of
antirejection therapy. What does one do when renal pathology
reveals no evidence of rejection in a patient with graft malfunc-
tion? In the early posttransplant period, in which renal artery
stenosis is a uncommon entity, the major causes of azotemia
despite "normal" pathology and a "normal" ultrasound in-
clude viral diseases and drug-induced nephrotoxicity as well as
"acute tubular necrosis." If clinical evidence of a viral disease
were present, we would greatly curtail the amount of immuno-
suppressive therapy administered. Almost invariably, graft
function improves as the patient becomes afebrile. In the
afebrile patient, we would strongly consider the diagnosis of
cyclosporine nephrotoxicity; we would reduce the drug dose
and eventually consider cessation of cyclosporine in favor of
azathioprine therapy.
DR. KASSIRER: Of course, the important question is how
accurately an interstitial infiltrate predicts reversible acute
rejection and how accurately the vasculitic finding indicates
irreversible rejection. Because, if indeed these histologic find-
ings are highly correlated with the therapeutic outcome, the
biopsy result would be very helpful in choosing therapy.
DR. STROM: We believe that renal biopsy is highly reliable in
revealing graft rejection and distinguishing reversible rejection
(cellular) from irreversible rejection (vasculitic). In addition,
almost invariably in patients with a normal biopsy lacking
clinical evidence of ATN or genitourinary tract or vascular
abnormalities, a reduction in immunosuppressive therapy re-
sults in improved graft function.
DR. MICHAEL MADAIO (Division of Nephrology, NEMC):
Since the approval of cyclosporine we have been questioning
whether we should begin using the drug. Two questions recur.
First, what are the long-term effects of cyclosporine therapy?
For example, is there an increased risk of malignancy? More
specifically, do these patients have a higher risk of lymphoma
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than do similar patients treated with more conventional immu-
nosuppressive therapy? Second, when these patients are re-
quired to pay for cyclosporine on their own, can they afford to
take it on a long-term basis?
DR. STROM: In patients treated with cyclosporine and ste-
roids, the incidence of neoplasia is comparable to that with
conventional therapy. The first group of cyclosporine-treated
patients had a very high incidence of neoplasia, but those
patients were treated with a fearsome combination of immuno-
suppressive drugs, for example, conventional treatment plus
cyclosporine. The incidence of neoplasm in cyclosporine-treat-
ed patients is approximately 1%. This figure includes heart and
bone marrow transplants, for which patients are treated more
intensively, such as with a high dosage of conventional agent
plus anti-T cell antibodies, and the incidence of neoplasm is
higher. There is a risk of lymphoma, as in other patients given
immunosuppressive therapy. Cyclosporine is not unique in this
regard. As for the high cost of cyclosporine, federal legislation
is pending that might provide funds for such treatment.
Finally, Morris et al used cyclosporine therapy over a 3-
month period; azathioprine then replaced the cyclosporine
without causing irreversible graft rejection [88]. This strategy
might reduce the potential for chronic interstitial nephritis
imposed by cyclosporine. In short, we know little of the long-
term adverse side effects of cyclosporine. We are embarked on
a troublesome learning experience; we hope to take advantage
of the short-term benefits of cyclosporine while avoiding the
adverse long-term toxicities and financial impact.
DR. MARK DESNOYERS (Medical Resident, NEMC): In a
recent report from Montreal [78], a number of conditions were
identified in which transplanted kidneys were at increased risk
from the nephrotoxic effects of cyclosporine. Such conditions
include preservation of donor kidneys more than 24 hours
before transplantation, and prolonged anastomosis time during
transplantation. Have you observed increased nephrotoxicity
of cyclosporine under such circumstances?
DR. STROM: Cyclosporine, a nephrotoxin, is dangerous in
circumstances in which the kidney is already compromised by
some other agent or physiologic state. Several adverse drug
interactions involve the concurrent use of cyclosporine and
other known nephrotoxins. In the Canadian, but not European
multicenter trial, the length of organ preservation and reanasto-
mosis time increased the incidence of cyclosporine nephrotox-
icity. Perhaps the use of adjunctive corticosteroids at the time
of transplantation in our unit prevents such nephrotoxicity; this
treatment was not given in the Canadian trial. I am optimistic
that cyclosporine can be used for transplants involving kidneys
that have been perfused for more than 24 hours.
DR. SYAMAL DATTA (Division of Hematology-Oncology,
NEMC): Did you observe modulation of the Tl2 antigen by the
monoclonal anti-Tl2 antibody?
DR. STROM: No, T12 does not modulate its target antigen;
OKT3, but not Tl2, modulates its antigen. This is one of the
reasons that we chose Tl2 for clinical trial in preference to
OKT3.
DR. DATTA: Did the patient produce any antibodies against
the mouse monoclonal antibody to Tl2 during therapy? This
could neutralize the efficacy of such therapy and bring about
immune complex-mediated damage to the grafts.
DR. STROM: A majority of patients getting T12 develop low
titer antimouse antibodies, always of the 1gM class, which
usually appear briefly after cessation of Tl2 therapy. Only one
patient developed urticaria during the course of treatment.
DR. DATTA: What is your opinion regarding therapy with
anti-DR or antiidiotypic antibodies directed against the T-cell
recognition structures that are specific for allogeneic transplan-
tation antigens?
DR. STROM: The use of anti-DR antibodies resulted in graft
damage. These antibodies reacted with the endothelium. The
use of antiidiotypic antibodies is an attractive idea, but I think it
will be difficult to use such antibodies in clinical practice
because there are so many transplant antigens and so many
potential idiotypes that might emerge in the context of an
allograft response. Even in well-defined genetic circumstances
provided by murine transplant models, efforts at developing
antiidiotypes for transplantation have failed. I cannot foresee
that such antibodies will be ready for clinical use in the near
future.
DR. LEVEY: I would like to return to the question of whether
transplantation should be considered the primary form of
therapy for end-stage renal disease. Like you, I also believe that
transplantation should be considered strongly for most of our
patients. However, I don't share your interpretation of the
survival data. Hutchinson et al [89, 90] and Vollmer et al [91]
demonstrated that life expectancy after the onset of renal failure
is shorter for older patients and for patients with other medical
problems in addition to renal failure. Characteristically, pa-
tients selected for renal transplantation are younger and have
fewer concomitant illnesses than do their counterparts who
remain on dialysis. It is likely that their improved survival in
part is due to their younger age and better health rather than to
the specific treatment applied. I think there is not yet sufficient
evidence that cadaveric renal transplantation confers increased
survival compared to maintenance dialysis. Instead, I think we
should encourage patients to undergo renal transplantation
because it seems as safe as dialysis, and because the quality of
life provided in most cases appears better.
DR. STROM: I can't take strong exception to that point of
view, but why is the onus of this type of question always
directed at the transplant physician or surgeon? The person
who controls the flow of patients—the dialyzing nephrologist—
always asks the transplanter: How can I trust you to take care
of my sick patients? Why is it not fair to ask a question in the
other direction? Recent data show, or at least strongly suggest,
that transplanted patients live longer and better than do dia-
lyzed patients. I agree that actuarial biases are operative, but
many acknowledge that the rate of rehabilitation and the long-
term survival with dialytic therapy is poor. Has the "dialyzer"
been made accountable for these depressing facts in an era of
greatly improved transplantation? The findings of Krakauer
strongly suggest that high-risk patients, such as diabetics and
elderly patients, who were transplanted between 1977 and 1980,
fare at least as well if not better than patients treated by dialysis
[92].
DR. KASSIRER: The improvement in the results of transplan-
tation raises a new question: now that the results with renal
transplantation are improved, should we withhold potentially
dangerous and not-very-effective steroid and/or cytotoxic ther-
apy in patients with progressive glomerulonephritis complicat-
ed by moderate to severe renal failure? Should we allow the
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kidneys of these patients to fail and then employ transplanta-
tion? If our success with transplantation is not yet good enough,
how effective will transplantation have to be before we opt to
withhold medical therapy? This problem affects many patients
with rapidly progressive glomerulonephritis, lupus nephritis,
and other glomerulonephritides.
DR. STROM: I agree that many such patients should not be
treated aggressively. Why expose patients to high risk in
circumstances in which the gains are likely to be minor and
transient?
DR. MADATO: The results you presented using cyclosporine
in rats that received heart transplants suggest that graft survival
coincides with the development of antigen-specific suppressor
cells. Do you think that is the mechanism of graft survival in
humans? If so, is cyclosporine more effective in promoting the
emergence of these cells?
DR. STROM: Some sketchy evidence points to the generation
of antigen-specific suppressor cells in circumstances of a suc-
cessful clinical transplant. Thomas examined the immune status
of recipients of long-engrafted parent-to-child transplants [931.
In mixed lymphocyte cultures involving such combinations,
one would expect to find both proliferation and development of
killer cells specific to the donor in culture. But Thomas found
that the killer cells failed to develop. These failures were due to
action of a population of suppressor cells within the culture.
Animal research also supports the view that long-term engraft-
ment is associated with a skew of immune reactivity into the
suppressor mode, Early events of the immune system are
geared towards amplification and generation of effector-cell
function. As time goes on, negative feedback influences come
into play. I would be surprised if most of our patients who have
long-lived kidney grafts do not have an abundance of suppres-
sor cells.
Reprint requests to Dr. T. Strom, Beth Israel Hospital, 300 Brookline
Avenue, Boston, Massachusetts 02215, USA
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